Maharashtra FDA Moves Ahead With Action Against Ajay Devgn in Vimal Elaichi Ad Case

Key facts

According to reporting by Shachi Chaturvedi, the Maharashtra Food and Drug Administration is refusing to halt enforcement protocols directed at actor Ajay Devgn, with agency leadership clarifying that his petition before the Bombay High Court does not impede state proceedings. The controversy stems from marketing campaigns featuring Devgn endorsing Vimal Elaichi, a silver-coated cardamom seed product manufactured under the overarching Vimal brand family, which is widely recognized across India for its pan masala and gutkha commodities.

State regulators issued formal notices demanding an explanation regarding the actor's promotional role, questioning whether the advertisements violate statutory prohibitions on promoting chewable tobacco and related intoxicants. Devgn subsequently approached the Bombay High Court, seeking judicial relief against the FDA's regulatory notices and questioning the jurisdiction and statutory validity of the state's actions against brand ambassadors.

Tukaram Mundhe, a senior Indian Administrative Service officer serving as the commissioner of the state food and drug regulator, confirmed that the department is proceeding with legal and administrative measures as prescribed by law. The regulatory body maintains that in the absence of an explicit judicial stay from the high court bench, statutory authorities are mandated to execute compliance protocols against parties involved in commercial endorsements that breach advertising standards and public health statutes.

Why it matters

The decision by the Maharashtra FDA to press forward with proceedings carries structural consequences for India's media, advertising, and entertainment industries. For decades, commercial manufacturers of chewing tobacco, gutkha, and pan masala have navigated strict statutory advertising bans by deploying surrogate product variants, primarily cardamom seeds and mouth fresheners branded under identical trade names, colour palettes, and packaging aesthetics. By holding celebrity brand ambassadors directly accountable for participating in such campaigns, regulatory bodies are testing the boundaries of endorser liability established under revised consumer protection statutes.

Under India's Consumer Protection Act of 2019, endorsers are legally required to conduct due diligence regarding the veracity and legal standing of the products they represent. Penalties for misleading or illegal advertisements can include financial fines reaching up to 5 million Indian rupees and statutory prohibitions on endorsing commercial goods for periods of up to three years. If administrative actions against marquee actors like Devgn withstand judicial scrutiny in the Bombay High Court, consumer protection bodies nationwide will hold a potent precedent to pursue top-tier cultural figures who participate in surrogate advertising.

Furthermore, the case strikes directly at the revenue architecture of major entertainment networks and digital platforms, where pan masala conglomerates invest heavily in seasonal marketing, particularly during televised sports leagues and film award ceremonies. A rigorous enforcement drive that deters mainstream celebrities from signing lucrative endorsement contracts would alter corporate marketing strategies across the domestic fast-moving consumer goods sector.

India has maintained strict statutory bans on the direct advertising of tobacco products since the enactment of the Cigarettes and Other Tobacco Products (Prohibition of Advertisement and Regulation of Trade and Commerce, Production, Supply and Distribution) Act, known as COTPA, in 2003. Furthermore, regulations framed by the Food Safety and Standards Authority of India (FSSAI) in 2011 explicitly banned the manufacture, storage, distribution, and sale of food products containing tobacco or nicotine as ingredients, leading states including Maharashtra to institute stringent prohibitions against gutkha and flavoured pan masala.

To circumvent comprehensive media bans, manufacturing conglomerates turned to surrogate marketing strategies, launching non-tobacco product lines such as "elaichi" (cardamom) or packaged drinking water under legacy brand names. These campaigns often feature high-profile cinematic stars utilizing memorable taglines and gestures that mimic historical tobacco promotions, drawing sustained criticism from medical organizations, public health advocacy networks, and oncologists.

The Central Consumer Protection Authority (CCPA), constituted under the Consumer Protection Act of 2019, subsequently issued the Guidelines for Prevention of Misleading Advertisements and Endorsements for Misleading Advertisements in June 2022. These federal rules expressly prohibited surrogate advertising, stipulating that advertisements cannot suggest, directly or indirectly, the availability of products whose advertising is prohibited by law. The guidelines placed an affirmative legal obligation upon endorsers to ensure their appearances do not promote prohibited categories through visual or verbal associations.

Within Maharashtra, administrative oversight of these provisions rests with the state FDA. The current commissioner, Tukaram Mundhe, has built a nationwide administrative reputation over two decades across numerous municipal and state postings for uncompromising enforcement of municipal codes, public health mandates, and institutional regulations, frequently clashing with commercial interests and political establishments in the process.

Reaction

Formal corporate responses have largely aligned along legal channels rather than public public-relations statements. Representatives for the actor have pursued judicial redress via the Bombay High Court, arguing through filings that the promotional material relates exclusively to an innocuous food product—cardamom seeds—which is lawfully sold and does not contain prohibited substances such as nicotine or tobacco.

Public health advocates and anti-tobacco non-governmental organizations in Maharashtra have consistently expressed support for rigorous state action against surrogate pan masala endorsements, pointing to epidemiological studies that link areca nut consumption and chewable stimulants to high domestic rates of oral submucous fibrosis and oral cancer. Public interest litigants have filed multiple petitions across high courts in Mumbai, Delhi, and Allahabad seeking comprehensive judicial bans on pan masala advertising and punitive measures against cultural figures who legitimize the brands.

The Advertising Standards Council of India (ASCI), a voluntary self-regulatory industry body, has repeatedly updated its codes regarding brand extensions, requiring companies to prove that surrogate products possess substantial independent distribution and sales volumes rather than existing merely as marketing cloaks for restricted goods. However, state administrative agencies operate independently of industry self-regulators, utilizing statutory penal provisions rather than voluntary guidelines.

What we don't know yet

Several substantive legal and procedural facts remain unresolved in the public record. The reporting does not disclose the specific statutory sections invoked by the Maharashtra FDA in its notices to Devgn, leaving unconfirmed whether the action is premised directly on FSSAI food safety regulations, state-level public health bans, or provisions delegated under the Consumer Protection Act.

Additionally, the current procedural posture before the Bombay High Court remains unstated. It is not yet clear whether the court has issued formal notices to the state government, heard preliminary arguments on interim relief, or scheduled a definitive hearing date to rule on the maintainability of Devgn’s petition. Furthermore, it is not publicly verified whether the FDA has issued parallel enforcement notices to the corporate manufacturers of Vimal Elaichi or other film industry figures who have appeared alongside Devgn in identical commercial campaigns.

What to watch

The trajectory of the dispute will depend primarily on the forthcoming judicial determination by the Bombay High Court. Observers should watch whether the high court bench grants an ad-interim stay against the Maharashtra FDA’s notices or declines to intervene, which would permit the state regulator to initiate formal penal proceedings or financial assessments against the actor.

Subsequent steps by the Maharashtra FDA will also warrant attention, specifically whether the department escalates the matter by filing a criminal complaint before a judicial magistrate or refers the dossier to the Central Consumer Protection Authority for nationwide endorsement disqualification. Finally, market analysts will be observing whether other state regulatory administrations adopt Maharashtra's aggressive stance against celebrity endorsers of pan masala brand extensions, or whether advertising agencies modify pending promotional contracts ahead of major television broadcasting events.

Reporting by Shachi Chaturvedi provided the foundational information regarding Tukaram Mundhe's confirmation of the Maharashtra Food and Drug Administration's ongoing proceedings against Ajay Devgn.